Table 3 Immunotherapeutic trials in patients with bone and soft tissue sarcoma
From: A quest for therapeutic antigens in bone and soft tissue sarcoma
Tumor | Clinical setting | Immune intervention | Immunological response | Clinical outcome | Reference |
|---|---|---|---|---|---|
Osteosarcoma | Post-definitive surgery | Autologous tumor cells | N.D | NED at 2y, 1 of 13 | 5,6 |
| Â | Post-definitive surgery | Autologous tumor lysate | N.D | NED at 2y, 7 of 16 | 5,6 |
| Â | Post-definitive surgery | Allogeneic tumor-sensitized lymphocytes | N.D | NED at 2y, 12 of 32 | 7,8 |
Synovial sarcoma | Advanced stage | SYT-SSX peptides-pulsed DC | Cyototoxicity, 1 of 1 | PD, 1 of 1 | 63 |
| Â | Advanced stage | SYT-SSX peptide | Cytotoxicity, 4 of 5 | NC, 1 of 6 | 61 |
Ewing sarcoma | Advanced stage | EWS-FLI1 peptide + IL-2 | T cell proliferation, 1 of 3 | PR, 1 of 12 | 49 |
Alveolar rhabdomyosarcoma | Advanced stage | PAX3-FKHR peptide + IL-2 | N.D | Response, none of 4 | 49 |
Various sarcomas | Advanced stage | Autologous tumor lysate-pulsed DC | DTH, 3 of 10 | PR, 1 of 10 | 62 |
| Â | Advanced stage | Autologous tumor cell line | DTH, 8 of 16 | Response, none of 12 | 60 |